Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Additional file 2 of BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

Autor: Liefaard, M. C., van der Voort, A., van Ramshorst, M. S., Sanders, J., Vonk, S., Horlings, H. M., Siesling, S., de Munck, L., van Leeuwen, A. E., Kleijn, M., Mittempergher, L., Kuilman, M. M., Glas, A. M., Wesseling, J., Lips, E. H., Sonke, G. S.

Additional file 2. Supplementary Tables.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0528771fefa256625ae4768e3a45996

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients

Autor: Neerincx, Anne H., Whiteson, Katrine, Phan, Joann L., Brinkman, Paul, Abdel-Aziz, Mahmoud I., Weersink, Els J.M., Altenburg, Josje, Majoor, Christof J., Maitland-van der Zee, Anke H., Bos, Lieuwe D.J., Haarman, E., Rutjes, N. W., Terheggen-Lagro, S. W.J., Seljogi, D., Kemper, E. M., Lutter, R., Vijverberg, S. J., Vonk, S. E.M., Adriaens, N., Lub, R., van Brederode, M., van der Schaaf, L., Verkleij, M., van Gilst, N. A., Hofsteenge, G. H., Brackel, C. L.H., Lakeman, P., Bon, I. C.M., Tanner, S. P.M., Sterk, P. J., Longo, C., Sinha, A., Fenn, D., Lammers, A., Richards, L. B., van Bragt, J. M., Kos, R., Dagelet, J. W.F., Lone-Latif, S. J.A., Schultz, M. J., Smit, M. R., Hagens, L. A.

Publikováno v: Neerincx, A H, Whiteson, K, Phan, J L, Brinkman, P, Abdel-Aziz, M I, Weersink, E J M, Altenburg, J, Majoor, C J, Maitland-van der Zee, A H, Bos, L D J, Haarman, E, Rutjes, N W, Terheggen-Lagro, S W J, Seljogi, D, Kemper, E M, Lutter, R, Vijverberg, S J, Vonk, S E M, Adriaens, N, Lub, R, van Brederode, M, van der Schaaf, L, Verkleij, M, van Gilst, N A, Hofsteenge, G H, Brackel, C L H, Lakeman, P, Bon, I C M, Tanner, S P M, Sterk, P J, Longo, C, Sinha, A, Fenn, D, Lammers, A, Richards, L B, van Bragt, J M, Kos, R, Dagelet, J W F, Lone-Latif, S J A, Schultz, M J, Smit, M R, Hagens, L A, Amsterdam mucociliary clearance disease research group & Amsterdam UMC Breath Research Group 2021, ' Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients ', ERJ Open Research, vol. 7, no. 2, 00731-2020 . https://doi.org/10.1183/23120541.00731-2020
ERJ Open Research, 7(2):00731-2020. BMJ Publishing Group
ERJ Open Research
article-version (VoR) Version of Record
ERJ open research, 7(2):00731-2020. European Respiratory Society
ERJ Open Research, Vol 7, Iss 2 (2021)

Rationale Targeted cystic fibrosis (CF) therapy with lumacaftor/ivacaftor partly restores chloride channel function and improves epithelial fluid transport in the airways. Consequently, changes may occur in the microbiome, which is adapted to CF lung

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab579d0ee582c686532e1520e3205a9
https://research.vumc.nl/en/publications/cdb44a8a-7c3d-44d5-8941-b1e909993ffb

P301 Step-wise introduction of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and liver cirrhosis Child-Pugh A or B using clinical- and therapeutic drug monitoring: a case series

Autor: Vonk, S., Lub, R., Weersink, E., Beuers, U., Mathôt, R., Kemper, M., Altenburg, J.

Publikováno v: In Journal of Cystic Fibrosis June 2023 22 Supplement 2:S157-S157

161P MammaPrint and BluePrint diagnostic tests can be robustly assessed on Whole-Transcriptome NGS platform

Autor: Liefaard, M.C., Bhaskaran, R., Bijl, Y., Israeli, D., Jong-Raadsen, S., van Montfort, E., Bao, S., Mee, S., Cavness, T., Gallagher, A., Falk, J., Piel, T., Witteveen, A., van der Voort, A., Vonk, S., Lips, E., Sonke, G.S., Kleijn, M., Glas, A., Mittempergher, L.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S612-S612